OMEICOS Therapeutics
Phase 2Lead compound OMT-28 has recently been tested in a double-blinded, placebo-controlled, multi-center Phase 2 clinical trial in patients suffering from atrial fibrillation. OMT-28 proved its excellent safety and tolerability profile, already shown in Phase I with 75 healthy volunteers.
Founded
2010
Focus
Small Molecules
About
Lead compound OMT-28 has recently been tested in a double-blinded, placebo-controlled, multi-center Phase 2 clinical trial in patients suffering from atrial fibrillation. OMT-28 proved its excellent safety and tolerability profile, already shown in Phase I with 75 healthy volunteers.
Funding History
2Series AUndisclosedUndisclosedJun 15, 2015
SeedUndisclosedUndisclosedJun 15, 2011
Company Info
TypePrivate
Founded2010
LocationBerlin, Germany
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile